Predictive value of early and late residual 18F-fluorodeoxyglucose and 
18F-fluorothymidine uptake using different SUV measurements in patients with 
non-small-cell lung cancer treated with erlotinib

Kobe, Carsten; Scheffler, Matthias; Holstein, Arne; Zander, Thomas; Nogova, Lucia; Lammertsma, Adriaan A.; Boellaard, Ronald; Neumaier, Bernd; Ullrich, Roland T.; Dietlein, Markus; Wolf, Johanna; Kahraman, Deniz

doi:10.1007/s00259-012-2118-8

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

MPS-Authors

/persons/resource/persons147352

Zander, Thomas
Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147249

Neumaier, Bernd
Radiochemistry, Scientific Services and Development, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147322

Ullrich, Roland T.
Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147154

Dietlein, Markus
Translational Neurocircuitry, Research Groups, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Kobe, C., Scheffler, M., Holstein, A., Zander, T., Nogova, L., Lammertsma, A. A., Boellaard, R., Neumaier, B., Ullrich, R. T., Dietlein, M., Wolf, J., & Kahraman, D. (2012). Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. European Journal of Nuclear Medicine and Molecular Imaging, 39(7), 1117-1127. doi:10.1007/s00259-012-2118-8.

引用: https://hdl.handle.net/11858/00-001M-0000-0026-D867-1